Navigation Links
Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

LAUSANNE, Switzerland, June 23 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that Salvacyl(R) (also known under the trade names Moapar(R) and Salvapar(R)), was launched in Germany in May 2009, by Dr R. Pfleger GmbH. In April 2009, Salvacyl(R) was also launched on a preliminary basis in Belgium. The effective commercial launch will take place in a couple of months. Salvacyl(R) contains the active substance triptorelin, a gonadotropin releasing hormone (GnRH) agonist analogue. The product will be prescribed for the reversible reduction of serum testosterone to the level of castration in order to lower sexual drive in adult men suffering from sexual deviations.

"This is a great accomplishment for Debiopharm. Salvacyl(R) is the fourth product we have developed and made available to doctors for the treatment of a serious condition," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "We can now offer people suffering from this controversial disorder an alternative and a complementary treatment to surgical and currently used chemical castrations, as well as to other types of medication."

Salvacyl(R) is registered in seven other European countries, including France, the United Kingdom, Sweden, Norway, Denmark, the Netherlands and Finland, and will be launched progressively by Debiopharm's commercial partners in the course of 2009 and 2010. Moapar(R) is currently undergoing a registration procedure with Swissmedic in Switzerland.

About Salvacyl(R)

In the treatment of sexual deviations in men, intra-muscular administration of Salvacyl(R) every 3 months, in combination with psychotherapy, is an advantage over daily oral forms or intra-muscular weekly injections that are required with anti-androgens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA). There are also fewer side effects.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit:

    Debiopharm S.A. Contacts
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69

    Additional Media Contacts
    In London
    Brian Hudspith
    Tel: +44(0)20-7379-5151

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. More Than 300 New Medicines Being Developed for Mental Illnesses
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists
9. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
10. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
(Date:11/25/2015)... Research and Markets ( ) has announced the ... to 2020" report to their offering. ... the total market share in 2014. The market for ... to growth at the highest CAGR between 2015 and ... fast growing water, industrial gas treatment, pharmaceutical, and food ...
Breaking Medicine Technology:
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination of recycled ... way for homeless people to have a more dignified and comfortable night’s sleep. ... they are repurposing plastic bags into sleeping mats for the homeless. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA , ... now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. This ... cutting tools, such as the scalpel and high-speed drill, which can both cause patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... ThirdLove, the ... sale a week early, offering 40% off select bras and underwear styles, now ... through both mobile fit technology and the latest fashion, quickly becoming the next ...
Breaking Medicine News(10 mins):